TY - JOUR T1 - Interferon gamma liposome; a new delivery system to improve drug delivery in the treatment of lung cancer JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00555-2020 SP - 2000555 AU - Maysa Alhawmdeh AU - Mohammad Isreb AU - Abid Aziz AU - Badie K. Jacob AU - Diana Anderson AU - Mojgan Najafzadeh Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/04/29/23120541.00555-2020.abstract N2 - Lung cancer is one of the main causes of death worldwide. Published data show the use of interferons (IFNs) in treating lung tumours. Also, IFNs present a potential for antiproliferative, anti-angiogenic, immunoregulatory, and proapoptotic effects. The IFN-γ functions as an anticancer agent against various forms of cancer. This study aimed to investigate the effect of IFN-γ liposome (nano) on peripheral lymphocyte from 20 individuals in each group; lung cancer patients, compared to healthy individuals. The effectiveness of IFN- γ liposome against oxidative stress was also evaluated in this study. A concentration of 100 U·mL−1 of IFN-γ liposome was used to treat the lymphocytes in the Comet and micronucleus assays based on the preliminary test for the optimal dose. The lymphocytes from lung cancer patients presented with higher DNA damage levels than those of healthy individuals. In healthy individuals, IFN-γ liposome didn't cause to induce any DNA damage in the lymphocytes. Also, it caused a significant reduction in DNA damage in the lymphocytes from lung cancer patients in both the Comet and micronucleus assays. The 100 U·mL−1 of IFN-γ liposome significantly reduced the oxidative stress caused by H2O2 and appeared to be effective in both groups using the Comet and micronucleus assays. Results from both Comet and micronucleus assays were consistent. The data obtained indicated that IFN-γ in both forms (INF-γ bulk and INF-γ nano-liposome) may potentially be effective for the treatment of lung cancer and showed the ability of IFN-γ liposome to reduce the DNA damage more than the bulk form.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Alhawmdeh has nothing to disclose.Conflict of interest: Isreb has nothing to disclose.Conflict of interest: Aziz has nothing to disclose.Conflict of interest: Jacob has nothing to disclose.Conflict of interest: Anderson has nothing to disclose.Conflict of interest: Dr. Najafzadeh has nothing to disclose. ER -